Why FDA recruitment of 'critics' is a problem

Abstract

volume 28 number 3 march 2010 nature biotechnology another drug on the market...didn’t appear to be sufficient reason” for approval2. But whether or not the advisory committee meant to convey that (and in any case, advisory committee recommendations are not binding), it is specious reasoning. In addition, post-marketing studies as a condition of approval… (More)
DOI: 10.1038/nbt0310-212a

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics